Nomura Real Estate Holdings reports strong earnings growth, but declining profit margins and demographic challenges in Japan pose risks.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
DaVita's Q3 earnings miss expectations, leading to a decline in share price, as the company faces cost and volume headwinds despite pockets of growth.
Nomura Real Estate Holdings reports strong earnings growth, but declining profit margins and demographic challenges in Japan pose risks.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
DaVita's Q3 earnings miss expectations, leading to a decline in share price, as the company faces cost and volume headwinds despite pockets of growth.